Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s LymphomaStephen M. Ansell, David J. Straus, Jonathan W. Friedberg et al.|New England Journal of Medicine|2022Cited by 342
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaOwen A. O’Connor, Muhıt Özcan, Eric D. Jacobsen et al.|Journal of Clinical Oncology|2019Cited by 154
First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)Owen A. O’Connor, Andrei R. Shustov, Muhıt Özcan et al.|Blood|2015Cited by 24
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 StudyNancy L. Bartlett, Marco Picardi, David J. Straus et al.|Blood|2019Cited by 1